| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 4.2K | 3.5% | 31.3% |
| Total Income | 4.2K | 4.1% | 32.0% |
| Expenditure | 3.6K | 5.4% | 6.9% |
| PBT | 338.29 | 47.4% | 65.0% |
| Net Profit | 263.83 | 45.4% | 56.8% |
| OPM | 11.78% | 8.25pp | 4.33pp |
| NPM | 6.21% | 5.61pp | 3.56pp |
| EPS | 9.35 | 45.4% | 56.8% |
Detailed report is being prepared.
US growth and product momentum to sustain Q2 pull-forward
After Q1's 23% YoY sprint, Glenmark eyes steady revenue and margin guidance as new launches and regulatory wins offset cost headwinds. Street consensus Build remains intact at 12% upside.
The Setup
Glenmark enters Q2 FY27 with momentum — Q1 revenue surged 23.1% YoY to ₹4,018.5 Cr on the back of US growth acceleration and India resilience. Management guides FY27 consolidated revenue in the ₹17,000–18,000 Cr range, implying steady mid-to-high-teen growth after the Q1 jump. The Street consensus (Buy; median target ₹2,575, +12% from current) is anchored to execution of this guide and the company's ability to sustain US momentum while maintaining the 21–22% EBITDA margin target amid cost headwinds.
~₹4,050 Cr
Implies ~20% YoY growth, assuming Q1 pace moderates slightly; on-plan for FY27 ₹17k–18k Cr guide
~21–22%
Management guidance for FY27; Q1 delivery in-line; freight & input cost inflation offset by volume
>₹225 Cr
Exceeding $100M USD (~₹900 Cr annualized); critical to FY27 growth thesis
₹480–520 Cr range
Q1 PAT ₹482.83 Cr (clean quarter, no exceptional items); tracking above ₹46.97 Cr prior year
What a Strong vs. Weak Q2 Looks Like
Strong: Revenue exceeds ₹4,100 Cr (>21% YoY), EBITDA margin at or above 22%, with US sales tracking >₹230 Cr, validating the >$100M quarterly target. New launches (Adapalene, Sugammadex, Ryaltris pediatric expansion) driving incremental traction post-FDA clearance in late Q1/early Q2. Regulatory news (Goa EIR, any additional FDA approvals) reinforces supply-chain confidence. Weak: Revenue slips below ₹3,950 Cr (deceleration to <18% YoY) or margin compresses below 20.5% signalling cost pass-through challenges. US business falters below ₹210 Cr, or key launches underperform. Any adverse regulatory news or supply-chain setback flags execution risk to FY27 guide.
On Track to FY27 Guidance?
Yes, provisionally. Q1 at +23% YoY exceeds the on-plan cadence for the ₹17,000–18,000 Cr guide, implying H2 can ease to 18–20% growth and still deliver upper-end guidance. The ₹18,000 Cr midpoint translates to ~₹4,500 Cr average quarterly; H2 needs ~₹4,200 Cr per quarter, well within reach if US and emerging markets sustain momentum. EBITDA margin of 21–22% is credible given Q1 delivery and the company's pricing power in specialty segments (RYALTRIS, oncology pipeline assets). Risk: geopolitical freight volatility and raw material input costs remain — management is watching but confident in volume offsets.
What the Street Says
Since Last Quarter — the Filings Scan
Aug 13
FY26 BRSR & AGM notices filed
Routine; ESG/governance
Aug 11
Glenmark USA settles $15.28M antitrust suit (Humana)
One-time charge; does not affect Q2 ops but reduces legal tail risk
Aug 20
US FDA approves Fluticasone Propionate Nasal Spray (bioequiv. Flonase®)
New generic launch; supports US revenue base post-Q2
Aug 21
US launches Calcium Gluconate Injection (bulk/single-dose vials)
Injectable generics revenue; modest contribution Q2+
Jul 28
US launches Sugammadex Injection 200/500 mg (bioequiv. BRIDION®); $1.6B market
High-value launch; significant Q2 contribution expected
Jul 21
FDA expands RYALTRIS® approval to children 6–12 years
Label expansion; incremental US pediatric revenue Q2+
Sep 11
Brazil: Launches RYALTRIS® Nasal Spray (regulatory approval ANVISA)
Emerging market expansion; modest Q2 uplift, ramp Q3+
Sep 23
Goa manufacturing facility: FDA EIR issued (VAI status)
Supply-chain confidence; no warning letters; clears pathway for future filings
Sep 28
Trading window closed (standard pre-result compliance)
Routine
Oct 06
US OTC: Adapalene Gel USP 0.1% launched in pump packs (bioequiv. Differin®); $45.8M market
Consumer OTC; steady revenue base; competitive but defensible
Summary: Nine major events; none are red flags. Regulatory wins dominate — three US FDA approvals (Fluticasone, RYALTRIS pediatric, implied Sugammadex+Adapalene prior), Goa facility EIR, and ANVISA approval for Brazil. Product launches are material — Sugammadex (high-value specialty generic on a $1.6B market), Adapalene (OTC expansion into retail), and RYALTRIS pediatric (label expansion in a blockbuster trajectory). The Humana settlement ($15.28M) is a one-time charge but removes legal uncertainty; management flagged this as a near-term overhang now cleared. Insider trading window closure on Sep 28 is routine pre-result compliance; no promoter pledges or block deals are disclosed. No material M&A, downgrades, or supply-chain shocks reported.
What to Watch on Result Day (Nov 5)
1 · US Revenue Run-Rate
Did Q2 US sales stay >₹225 Cr (annualized >$100M)? This is the linchpin of FY27 growth and Street credibility. Watch for segment-wise breakout: specialty (RYALTRIS, Sugammadex) vs. generics. A miss here reprices risk.
2 · Consolidated EBITDA Margin
Can management hold 21–22% despite freight/input inflation? Q1 delivered 23.9% (clean quarter), but the guide assumes 21–22%. Management's commentary on cost inflation trajectory will guide FY27 Q3–Q4 expectations and margin sustainability.
3 · FY27 Guide Confirmation & New Product Traction
Reaffirm ₹17k–18k Cr revenue and 21–22% EBITDA margin for FY27? Any commentary on Sugammadex, Adapalene, RYALTRIS pediatric adoption curves? Early traction signals are key to H2 visibility. Watch for oncology pipeline updates (ISB 2301 IND filing timeline).
Glenmark enters Q2 FY27 with the Street's confidence intact — Q1's 23% YoY beat, a Buy consensus at +12% upside, and a credible FY27 guide (₹17k–18k Cr) underpinned by US growth and new product momentum. The regulatory wins and product launches since Q1 (Sugammadex, Adapalene, RYALTRIS expansion, Goa EIR) signal execution capability; the Humana settlement removes a known overhang. Margins are the secondary watch — cost inflation is real, but management's pricing power and operational leverage in specialty segments suggest 21–22% is achievable. Q2 is unlikely to surprise the market structurally, but execution on US traction and margin guidance will reset FY27 trajectory and validate the 12% target-price upside.
Three key vectors: US revenue >₹225 Cr (sustainability test), EBITDA margin 21–22% (cost discipline), and any material guidance revisions or pipeline updates (visibility). If all three hold, consensus stands; any slip on US or margins could trigger a de-rate into H2.